Definitive Healthcare Corp. — FY 2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. This is an annual filing, not a standalone fourth-quarter report; quarter-specific detail is noted where disclosed. Definitive Healthcare provides subscription-based healthcare commercial intelligence and reported approximately 2,900 customers at year-end.
Financial performance and position
| Metric | FY 2023 | FY 2022 |
|---|---|---|
| Revenue | $251.4 million | $222.7 million |
| Revenue growth | 12.9% | — |
| Gross profit / GAAP gross margin | $203.9 million / 81% | $180.0 million / 81% |
| Operating loss | $329.8 million | $44.0 million |
| Net loss | $289.6 million | $24.2 million |
| Adjusted EBITDA / margin | $74.5 million / 30% | $63.7 million / 29% |
| Cash from operating activities | $41.2 million | $35.6 million |
- Subscription services generated $243.1 million, or approximately 97% of revenue; professional services contributed $8.4 million.
- Revenue growth came from new customers, Populi, and increased revenue from existing customers. However, total customers declined to approximately 2,900 from approximately 3,000.
- Total NDR fell to 91% from 102%. Enterprise-customer NDR was 96% versus 110%; NDR for customers above $17,500 ARR was 92% versus 103%. Enterprise customers numbered 565 and represented approximately 65% of ARR.
- Year-end cash and cash equivalents were $131.0 million and short-term investments were $177.1 million. The company reported $74.4 million available under its revolving credit facility. Management believes liquidity is sufficient for at least the next 12 months.
- Term-loan principal was $257.8 million, with a 7.21% effective interest rate; no revolver balance was outstanding. The facilities mature in September 2026, including an approximately $220 million balloon payment. The company was in compliance with financial covenants at year-end.
- Current remaining performance obligations were $187.3 million; total remaining performance obligations were $277.0 million, essentially unchanged from 2022. Management cautions that this metric is affected by contract terms, renewals, and cancellation provisions.
Material changes and unusual items
- A $287.4 million non-cash goodwill impairment charge, recorded in Q3 after a sustained decline in share price and market capitalization, drove much of the increase in GAAP losses. The impairment did not affect liquidity or debt covenants. The company concluded that reporting-unit fair value exceeded carrying value at year-end, but disclosed risk of future impairment.
- The company restated previously issued financial statements after finding material sales-tax misstatements. It accrued sales taxes, interest, and penalties for jurisdictions where tax had not been collected. The sales-tax accrual was $6.7 million at December 31, 2023; the company is pursuing voluntary disclosure agreements.
- Management identified an unremediated material weakness in controls over sales-tax collection, remittance, and recording. Management and the auditor concluded internal control over financial reporting was ineffective at year-end; Deloitte issued an adverse opinion on internal controls but an unqualified opinion on the financial statements.
- Populi was acquired in July 2023 for $54.1 million of total consideration, including contingent consideration; its purchase-price allocation remained provisional. In January 2024, the company acquired Carevoyance assets for $14.0 million, subject to closing adjustments.
- 2023 restructuring plans reduced headcount by approximately 100 and incurred $4.7 million of charges. A January 2024 plan provides for 154 further employee reductions; management estimates $6.5–$7.2 million of cash charges and approximately $1.5 million of non-cash stock-compensation charges in the first half of 2024.
- Goodwill was $1.075 billion and net intangible assets were $323.1 million at year-end, making asset valuation and future impairment significant considerations.
Outlook, management commentary, and risks
- Management expects 2024 revenue growth to be lower than 2023, citing longer sales cycles, stricter customer approvals, deferred purchases, and heightened churn, particularly among smaller customers and in life sciences and provider markets. Management said these trends are expected to continue into 2024 while the company addresses underlying issues.
- Management expects gross profit to increase in 2024 but gross margin to decrease modestly, reflecting expanded third-party data sources and Populi-related costs. Cost of revenue as a percentage of revenue is expected to remain consistent or increase modestly.
- Key business risks include customer churn and weaker expansion, competition and pricing pressure, dependence on third-party data and cloud providers, data accuracy and security, evolving privacy and AI regulation, and macroeconomic and geopolitical uncertainty. The business is highly subscription-dependent.
- Other items to monitor include the sales-tax remediation and related liabilities; the company’s ability to realize expected restructuring savings; variable-rate debt exposure despite interest-rate swaps; and the Tax Receivable Agreement, under which 85% of certain realized or deemed tax benefits may be payable to pre-IPO parties. The recorded TRA liability was $147.1 million, with a further $148.6 million potentially recorded if additional tax benefits are expected to be realized.
- The company reported no current plan to pay dividends. Management said ordinary-course legal proceedings are not expected to have a material adverse effect.
Most important facts for investors to verify
- Whether customer churn stabilizes and NDR improves from 91%, especially in smaller-customer, life-sciences, and provider segments.
- Whether the 2024 growth outlook and revenue trajectory align with actual renewals, sales cycles, cRPO, and customer spending.
- Progress and independent validation of sales-tax control remediation, voluntary disclosure agreements, and final tax liabilities; confirm the restated comparative figures used for analysis.
- Whether restructuring delivers sustainable savings without impairing sales, product development, customer support, or retention.
- Debt repayment capacity, interest-rate exposure, covenant headroom, and the 2026 maturity and balloon payment, alongside cash and investment liquidity.
- Future goodwill impairment tests and the assumptions supporting the carrying value of goodwill and acquired intangible assets.